المؤلفون: Willis, Joseph, Anders, Robert, Torigoe, Toshihiko, Hirohashi, Yoshihiko, Bifulco, Carlo, Zlobec, Inti, Mlecnik, Bernhard, Demaria, Sandra, Choi, Won-Tak, Dundr, Pavel, Tatangelo, Fabiana, Di Mauro, Annabella, Baldin, Pamela, Bindea, Gabriela, Marliot, Florence, Haicheur, Nacilla, Fredriksen, Tessa, Kirilovsky, Amos, Buttard, Bénédicte, Vasaturo, Angela, Lafontaine, Lucie, Maby, Pauline, El Sissy, Carine, Hijazi, Assia, Majdi, Amine, Lagorce, Christine, Berger, Anne, Van den Eynde, Marc, Pagès, Franck, Lugli, Alessandro, Galon, Jérôme

المصدر: Cancers. 15(16)

مصطلحات موضوعية: T cell, anatomopathology, colon cancer, digital pathology, immunoscore, prognostic markers, risk stratification, tumor microenvironment

الوصف: BACKGROUND: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune response in cancer patients. This study reports on the reproducibility of pathologists visual assessment of CD3+- and CD8+-stained colon tumors, compared to IS quantification. METHODS: An international group of expert pathologists evaluated 540 images from 270 randomly selected colon cancer (CC) cases. Concordance between pathologists T-score, corresponding hematoxylin-eosin (H&E) slides, and the digital IS was evaluated for two- and three-category IS. RESULTS: Non-concordant T-scores were reported in more than 92% of cases. Disagreement between semi-quantitative visual assessment of T-score and the reference IS was observed in 91% and 96% of cases before and after training, respectively. Statistical analyses showed that the concordance index between pathologists and the digital IS was weak in two- and three-category IS, respectively. After training, 42% of cases had a change in T-score, but no improvement was observed with a Kappa of 0.465 and 0.374. For the 20% of patients around the cut points, no concordance was observed between pathologists and digital pathology analysis in both two- and three-category IS, before or after training (all Kappa < 0.12). CONCLUSIONS: The standardized IS assay outperformed expert pathologists T-score evaluation in the clinical setting. This study demonstrates that digital pathology, in particular digital IS, represents a novel generation of immune pathology tools for reproducible and quantitative assessment of tumor-infiltrated immune cell subtypes.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5p41c8z2Test

المؤلفون: Ajani, Jaffer, El Hajbi, Farid, Cunningham, David, Alsina, Maria, Thuss-Patience, Peter, Scagliotti, Giorgio V, Van den Eynde, Marc, Kim, Sung-Bae, Kato, Ken, Shen, Lin, Li, Liyun, Ding, Ningning, Shi, Jingwen, Barnes, Gisoo, Van Cutsem, Eric

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer

المصدر: ESMO open, Vol. 9, no.1, p. 102202 [1-9] (2024)

مصطلحات موضوعية: Humans, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Quality of Life, Antibodies, Monoclonal, Humanized, anti-programmed cell death protein 1 antibody, tislelizumab

الوصف: BACKGROUND: The phase III RATIONALE-302 study evaluated tislelizumab, an anti-programmed cell death protein 1 antibody, as second-line (2L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC). This prespecified exploratory analysis investigated outcomes in patients from Europe and North America (Europe/North America subgroup). PATIENTS AND METHODS: Patients with tumor progression during/after first-line systemic treatment were randomized 1 : 1 to open-label tislelizumab or investigator's choice of chemotherapy (paclitaxel, docetaxel, or irinotecan). RESULTS: The Europe/North America subgroup comprised 108 patients (tislelizumab: n = 55; chemotherapy: n = 53). Overall survival (OS) was prolonged with tislelizumab versus chemotherapy (median: 11.2 versus 6.3 months), with a hazard ratio (HR) of 0.55 [95% confidence interval (CI) 0.35-0.87]; HR was similar irrespective of programmed death-ligand 1 score [≥10%: 0.47 (95% CI 0.18-1.21); <10%: 0.55 (95% CI 0.30-1.01)]. Median progression-free survival was 2.3 versus 2.7 months with tislelizumab versus chemotherapy [HR: 0.97 (95% CI 0.64-1.47)]. Overall response rate was greater with tislelizumab (20.0%) versus chemotherapy (11.3%), with more durable response (median duration of response: 5.1 versus 2.1 months). Tislelizumab had a favorable safety profile versus chemotherapy, with fewer patients experiencing ≥grade 3 treatment-related adverse events (13.0% versus 51.0%). Those on tislelizumab experienced less deterioration in health-related quality of life, physical functioning, and/or disease- and treatment-related symptoms (i.e. fatigue, pain, and eating problems) as compared to those on chemotherapy, per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and QLQ-OES18 scores. CONCLUSIONS: As a 2L therapy for advanced/metastatic ESCC, tislelizumab improved OS and had a favorable safety profile as compared to chemotherapy in European/North American ESCC patients in the ...

العلاقة: boreal:285071; http://hdl.handle.net/2078.1/285071Test; info:pmid/38118368; urn:EISSN:2059-7029

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.102202Test
http://hdl.handle.net/2078.1/285071Test

المؤلفون: Raghav, Kanwal Pratap Singh, Siena, Salvatore, Takashima, Atsuo, Kato, Takeshi, Van den Eynde, Marc, Di Bartolomeo, Maria, Komatsu, Yoshito, Kawakami, Hisato, Peeters, Marc, Andre, Thierry, Lonardi, Sara, Yamaguchi, Kensei, Tie, Jeanne, Gravalos Castro, Cristina, Strickler, John H, Barrios, Daniel, Yan, Qi, Kamio, Takahiro, Kobayashi, Kojiro, Yoshino, Takayuki, American Society of ClinicalOncology (ASCO)2023

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'hépato-gastro-entérologie, UCL - (SLuc) Service d'oncologie médicale

المصدر: Journal of Clinical Oncology, Vol. 41, no.16_suppl, p. 3501-3501 (2023)

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Background: T-DXd (6.4 mg/kg, every 3 weeks [Q3W]) demonstrated antitumor activity in pts with HER2+ mCRC in DESTINY-CRC01 (Siena et al. Lancet Oncol. 2021). We present primary results of DESTINY-CRC02 (NCT04744831), which assessed the efficacy and safety of T-DXd (5.4 and 6.4 mg/ kg) in pts with HER2+ mCRC. Methods: This was a multicenter phase 2 study. Eligible pts had centrally confirmed HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) mCRC. Pts with RAS wild-type (wt) or mutant (m) mCRC were eligible. Pts had received prior standard therapy, unless contraindicated; prior anti-HER2 therapy was allowed. In stage 1, 80 pts were randomized 1:1 to 5.4 (n = 40) or 6.4 (n = 40) mg/kg T-DXd Q3W. In stage 2, an additional 42 pts received 5.4 mg/kg TDXd. Primary endpoint was confirmed objective response rate (cORR) by blinded independent central review (BICR). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Results: At data cutoff (Nov 1, 2022), most pts in the 5.4 and 6.4 mg/kg T-DXd arms had HER2 IHC 3+ (78.0% and 85.0%), RAS wt tumors (82.9% and 85.0%), and a median of 3 and 4 prior lines of therapy, respectively. cORR was 37.8% (95% CI, 27.3-49.2%) in the 5.4 mg/kg arm and 27.5% (95% CI, 14.6-43.9%) in the 6.4 mg/kg arm (all partial responses in both arms). Key efficacy data are shown in the Table: Grade $3 treatment-emergent adverse events (AEs) were observed in 41/83 pts (49.4%) and 23/39 pts (59.0%) in the 5.4 and 6.4 mg/kg T-DXd arms, respectively. Serious AEs were observed in 20/83 pts (24.1%) and 12/39 pts (30.8%) in the 5.4 and 6.4 mg/kg arms, respectively. Independently adjudicated drug-related interstitial lung disease occurred in 7/83 pts (8.4%) with 5.4 mg/kg T-DXd and 5/39 pts (12.8%) with 6.4 mg/kg T-DXd, and most events were grade 1/2 (1 grade 5 in the 6.4 mg/kg arm). Conclusions: T-DXd showed promising antitumor activity in pts with HER2+ mCRC at both 5.4 and 6.4 mg/kg doses. Antitumor efficacy ...

العلاقة: boreal:277898; http://hdl.handle.net/2078.1/277898Test; urn:ISSN:0732-183X; urn:EISSN:1527-7755

الإتاحة: https://doi.org/10.1200/jco.2023.41.16_suppl.3501Test
http://hdl.handle.net/2078.1/277898Test

المؤلفون: Huyghe, Nicolas, Benidovskaya, Elena, Masoodi, Tariq, Carrasco, Javier, De Cuyper, Astrid, Sinapi, Isabelle, Vempalli, Fazulur, Verstraelen, Eleonore, Goffette, Pierre, Ghaye, Benoît, Papier, M., Bedognetti, Davide, van Maanen, Aline, Castella, Marie-Laure, Galon, Jérôme, Van den Eynde, Marc, ESMO Congress 2023

المساهمون: UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Clinical Trial Center, UCL - (SLuc) Service de radiologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: Annals of Oncology, Vol. 34, no.Suppl 1, p. S1152 (2023)

مصطلحات موضوعية: Oncology, Hematology

الوصف: BACKGROUND : This trial explores the clinical efficacy and safety of AVE, CET and IRI for treatment refractory MSS mCRC. We aim at characterizing the immune response for biomarker discovery through associated translational research. [.]

العلاقة: boreal:285072; http://hdl.handle.net/2078.1/285072Test; urn:ISSN:0923-7534; urn:EISSN:1569-8041

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.1265Test
http://hdl.handle.net/2078.1/285072Test

المؤلفون: Stevens, Philippe, Llorens-Rico, V., Benidovskaya, Elena, Baldin, Paméla, Coubeau, Laurent, Lacroix, valérie, Léonard, Daniel, Bachmann, Radu, Craciun, Ligia, Gofflot, Stéphanie, George, Fabienne, Sandras, Flavienne, Sadones, Jan, Buys, Magali, Raes, Jeroen, Van den Eynde, Marc, ESMO Congress 2023

المساهمون: UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (MGD) Service d'anatomie pathologique, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: Annals of Oncology, Vol. 34, no.Suppl 1, p. S423 (2023)

مصطلحات موضوعية: Oncology, Hematology

الوصف: BACKGROUND: Early evidence suggested a role of tissue-resident microbiota (TRM) in the development of colorectal cancer. However, its presence in colorectal cancer metastases (CRCM) is poorly reported. Here, we aim to explore and characterize the TRM in CRCM. [.]

العلاقة: boreal:285075; http://hdl.handle.net/2078.1/285075Test; urn:ISSN:0923-7534; urn:EISSN:1569-8041

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.1769Test
http://hdl.handle.net/2078.1/285075Test

المؤلفون: Carrasco, Javier, Beniuga, Gabriela, Mourin, Anne, Baldin, Paméla, Sinapi, Isabelle, Schroeder, David, De Cuyper, Astrid, Sclafani, Francesco, Hendlisz, Alain, van Laethem, Jean-Luc, Boulanger, Anne-Sophie, Van Ooteghem, Geneviève, Dermine, Alexandre, Delmarcelle, Sophie, Huyghe, Nicolas, Bar, Isabelle, Van den Eynde, Marc, ESMO Congress 2023

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service de radiothérapie oncologique, UCL - (SLuc) Centre du cancer

المصدر: Annals of Oncology, Vol. 34, no.Suppl 1, p. S432 (2023)

مصطلحات موضوعية: Oncology, Hematology

الوصف: BACKGROUND : There is a strong rationale to combine radiotherapy with immune checkpoint inhibitors (ICIs). This study evaluates this combination before surgery in locally advanced rectal cancer (LARC). [.]

العلاقة: boreal:285081; http://hdl.handle.net/2078.1/285081Test; urn:ISSN:0923-7534; urn:EISSN:1569-8041

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.1790Test
http://hdl.handle.net/2078.1/285081Test

المؤلفون: Van den Eynde, Marc, Huyghe, Nicolas, Sinapi, Isabelle, De Cuyper, Astrid, Verstraelen, Eleonore, Goffette, Pierre, Ghaye, Benoît, Papier, Matthias, Bedognetti, Davide, van Maanen, Aline, Castella, Marie-Laure, Galon, Jerôme, Carrasco, Javier, ESMO Congress 2023

المساهمون: UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Clinical Trial Center, UCL - (SLuc) Service de radiologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: Annals of Oncology, Vol. 34, no.Suppl 1, p. S450 (2023)

مصطلحات موضوعية: Oncology, Hematology

الوصف: BACKGROUND : Cetuximab could mediate, independently from RAS mutation, an immunogenic tumor cell death and antitumor immune response. This trial explores the efficacy and safety of AVE, CET and IRI for the treatment of refractory MSS mCRC. [.]

العلاقة: boreal:285089; http://hdl.handle.net/2078.1/285089Test; urn:ISSN:0923-7534; urn:EISSN:1569-8041

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.1825Test
http://hdl.handle.net/2078.1/285089Test

المؤلفون: Alexis, Lynn Gabrielle, Dano, Hélène, Dekairelle, Anne-France, van Marcke, Cédric, Van den Eynde, Marc

المساهمون: UCL - (SLuc) Unité d'oncologie médicale, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service d'hépato-gastro-entérologie

المصدر: Digestive and liver disease, Vol. 55, no. 3, p. 426-428 (2023)

مصطلحات موضوعية: Gastro-oesophageal adenocarcinoma, HER2, MSI, Molecular heterogeneity

الوصف: DEAR EDITOR, Gastro-oesophageal adenocarcinomas (GOAs) are a common cause of cancer mortality worldwide. Nowadays, beyond histological classification, the management of GOAs depends on molecular classification. The Cancer Genome Atlas consortium identified four different molecular subtypes of GOAs potentially allowing to tailor the treatment strategies [.].

العلاقة: boreal:270378; http://hdl.handle.net/2078.1/270378Test; info:pmid/36577596; urn:ISSN:1590-8658; urn:EISSN:1878-3562

الإتاحة: https://doi.org/10.1016/j.dld.2022.11.023Test
http://hdl.handle.net/2078.1/270378Test

المؤلفون: Aparicio, Thomas, Bouché, Olivier, Etienne, Pierre-Luc, Barbier, Emilie, Mineur, Laurent, Desgrippes, Romain, Guérin-Meyer, Véronique, Hocine, Fayçal, Martin, Jean, Le Brun-Ly, Valérie, Cretin, Jacques, Desramé, Jérôme, Rinaldi, Yves, Cany, Laurent, Falandry, Claire, Lefevre, Leila Bengrine, Marous, Miguelle, Terrebonne, Eric, Mosser, Laurent, Turpin, Justine, Turpin, Anthony, Bauguion, Lucille, Reichling, Cynthia, Van den Eynde, Marc, Carola, Elisabeth, Hiret, Sandrine

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: Digestive and liver disease, Vol. 55, no. 4, p. 541-548 (2023)

مصطلحات موضوعية: Gastroenterology, Hepatology

الوصف: BACKGROUND: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in older patients. METHODS: The purpose of ADAGE-PRODIGE 34, randomized open phase III trial is to compare in patients over 70 years oxaliplatin plus fluoropyrimidine with fluoropyrimidine alone in fit patients (Group 1) and fluoropyrimidine with observation in frail patients (Group 2) after resection of stage III colon adenocarcinoma. We report a preliminary tolerance analysis on 50% of the first patients enrolled. RESULTS: The analysis was conducted on 491 patients (378 in Group 1 and 113 in Group 2). Patients in Group 2 were older and showed more frailty criteria than those in Group 1. Cumulative grade 3-5 toxicities were more frequent in patients treated with oxaliplatin in Group 1 or with fluoropyrimidine in Group 2 than in patients treated with fluoropyrimidine in Group 1. At least one course was deferred in more than half of the patients in all groups. Early treatment cessation was more frequent in Group 2. CONCLUSION: No safety concerns were raised for the continuation of accrual. The frailty criteria distribution suggests that the investigator's evaluation for group allocation was accurate.

العلاقة: boreal:273022; http://hdl.handle.net/2078.1/273022Test; info:pmid/; urn:ISSN:1590-8658; urn:EISSN:1878-3562

الإتاحة: https://doi.org/10.1016/j.dld.2022.08.036Test
http://hdl.handle.net/2078.1/273022Test

المؤلفون: Huyghe, Nicolas, Benidovskaya, Elena, Beyaert, Simon, Daumerie, Aurélie, Maestre Osorio, Finoula, Aboubakar Nana, Frank, Bouzin, Caroline, Van den Eynde, Marc

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service de pneumologie, UCL - (SLuc) Centre du cancer

المصدر: Journal of visualized experiments, Vol. 196, p. e65220 [1-17] (2023)

مصطلحات موضوعية: General Immunology and Microbiology, General Biochemistry, Genetics and Molecular Biology, General Chemical Engineering, General Neuroscience

الوصف: The tumor microenvironment (TME) is composed of a plethora of different cell types, such as cytotoxic immune cells and immunomodulatory cells. Depending on its composition and the interactions between cancer cells and peri-tumoral cells, the TME may affect cancer progression. The characterization of tumors and their complex microenvironment could improve the understanding of cancer diseases and may help scientists and clinicians to discover new biomarkers. We recently developed several multiplex immunofluorescence (mIF) panels based on tyramide signal amplification (TSA) for the characterization of the TME in colorectal cancer, head and neck squamous cell carcinoma, melanoma, and lung cancer. Once the staining and scanning of the corresponding panels are completed, the samples are analyzed on an image analysis software. The spatial position and the staining of each cell are then exported from this quantification software into R. We developed R scripts that allow us not only to analyze the density of each cell type in several tumor compartments (e.g. the center of the tumor, the margin of the tumor, and the stroma) but also to perform distance-based analyses between different cell types. This particular workflow adds a spatial dimension to the classical density analysis already routinely performed for several markers. mIF analysis could allow scientists to have a better understanding of the complex interaction between cancer cells and the TME and to discover new predictive biomarkers of response to treatments, such as immune checkpoint inhibitors, and targeted therapies.

العلاقة: boreal:277878; http://hdl.handle.net/2078.1/277878Test; info:pmid/; urn:EISSN:1940-087X

الإتاحة: https://doi.org/10.3791/65220Test
http://hdl.handle.net/2078.1/277878Test